What did @drchaudhrysurgeon actually say?
The creator ran through a rapid-fire Q&A about a drug they're calling "Zip down" — almost certainly tirzepatide (Zepbound/Mounjaro) — comparing it favorably to semaglutide (Ozempic/Wegovy). The core claims: it outperforms Ozempic for weight loss, improves blood sugar and insulin resistance, reduces "food noise," and causes GI side effects and gallbladder issues in some users. The one genuinely interesting claim came at the end: "once you stop using it, the food noise actually gets worse."
That last point deserves attention because it's more specific and clinically relevant than most GLP-1 content on TikTok. The rest? A mix of things that are well-supported, one that's overstated, and one that needs real unpacking.
Does the science back this up?
On the head-to-head weight loss question, yes, the data is fairly clear. Tirzepatide does produce greater average weight loss than semaglutide, at least at the doses studied. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide achieving up to 22.5% body weight reduction at the highest dose. The STEP 1 trial for semaglutide 2.4mg (Wilding et al., 2021, NEJM) showed approximately 14.9%. No head-to-head RCT has been completed yet, but indirect comparisons consistently favor tirzepatide.
The food noise claim is more complicated. "Food noise" is not a clinical endpoint in these trials, but patient-reported outcomes data and the mechanism of dual GIP/GLP-1 agonism do suggest tirzepatide may have stronger effects on appetite signaling than GLP-1 alone. The claim that food noise worsens after stopping is biologically plausible, given what we know about GLP-1 receptor downregulation and rebound appetite, but it hasn't been rigorously tested as a primary outcome.
What did they get wrong (or right)?
They got several things right. The GI side effect profile, the gallbladder risk with rapid weight loss, and the acknowledgment that not everyone can tolerate it are all accurate and appropriately caveated. Gallstone risk with significant weight loss is well-documented (Erlinger, 2000, Gut), and tirzepatide's rapid weight loss trajectory does put some patients at higher risk.
The insulin resistance claim is accurate. Tirzepatide improves insulin sensitivity beyond what weight loss alone would explain, likely through GIP receptor agonism in adipose tissue (Min et al., 2021, Cell Metabolism).
The weakest claim is the binary "better than Ozempic" framing. Tirzepatide produces more weight loss on average, but individual response varies significantly. Some patients do better on semaglutide. The creator's phrasing doesn't leave room for that nuance, which matters when patients are making medication decisions.
The "food noise gets worse after stopping" claim is the most interesting and least proven. It tracks with clinical experience reported by prescribers, but calling it an established fact rather than an observed pattern is a stretch.
What should you actually know?
Tirzepatide is a dual GIP/GLP-1 receptor agonist, which is mechanistically different from semaglutide. That difference likely explains the superior weight loss numbers, but it also changes the side effect profile and tolerability for individual patients. "Better" is a population-level average, not a guarantee for any specific person.
The GI and gallbladder risks are real and worth discussing with a prescriber before starting. Rapid weight loss, regardless of the drug causing it, increases gallstone risk, and tirzepatide's efficacy is, paradoxically, part of what makes this a consideration.
On the food noise rebound: the honest answer is we don't have strong long-term data yet. Observational reports suggest appetite and cravings do return after discontinuation, sometimes intensely. This is one of the strongest arguments for treating obesity as a chronic condition requiring ongoing management rather than a short course of medication.
If you're considering either medication, the right conversation is with a clinician who can review your metabolic history, not a TikTok Q&A.